Injectable Steroids

Boldenone Undecylenate 250 mg Somatrop-Lab

Somatrop-Lab

55,00

In Stock (100 available)

Boldenone Undecylenate 250 mg Somatrop-Lab (250 mg) — With an exceptionally long half-life of approximately 14 days, Boldenone Undecylenate provides the most stable blood levels of any…

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Boldenone Undecylenate 250 mg Somatrop-Lab — boldenone undecylenate from Somatrop-Lab at 250 mg. The 14-day half-life is among the longest of any injectable steroid — expect 6–8 weeks for full onset, and plan cycle length (14–20 weeks) accordingly.

Key Benefits

  • Slow, steady lean-mass accrual — the patient lifter’s compound
  • Increased RBC production and vascularity
  • Mild oestrogenic conversion — AI usually sufficient at low dose
  • Appetite enhancement supports off-season caloric surpluses
  • Minimal androgenic sides at typical performance doses
  • Each unit dosed at 250 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 400–600 mg/week. Often front-loaded at 800 mg week 1 to speed up saturation (long ester takes 5+ weeks otherwise). Cycles 14–20 weeks. Above 800 mg/week lipid and BP effects grow without proportional gain.

How It Works

Dihydrotestosterone with a 1,2-double bond — structurally close to methandienone but without the 17α-methyl group, so no oral bioavailability and no hepatotoxicity. Converts weakly to estradiol (~half the rate of testosterone). Also metabolises to a hydroxylated form that can act as a mild AI itself.

Pharmacokinetics

Undecylenate ester. Plasma half-life approximately 14 days. Steady-state at 4–5 weeks without front-load; 2 weeks with. Weekly or bi-weekly pinning fine. Long clearance — PCT at week 3 post-last-injection.

Cycle & Stacking Guide

Long lean-gain cycles 16–20 weeks. Classic pairing: test E 400 mg/week + EQ 600 mg/week + (optional) winstrol or anavar for final 6 weeks. Not a first-cycle compound — long duration demands disciplined bloodwork and diet.

Manufacturer Notes

Somatrop-Lab specialises in growth-hormone and peptide products with lyophilised format and strict cold-chain documentation.

Storage & Handling

Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Boldenone Undecylenate 250 mg Somatrop-Lab”

Your email address will not be published. Required fields are marked *

Boldenone Undecylenate

Physical & Chemical Properties for Research Purposes
Chemical structure of Boldenone Undecylenate (C30H44O3) for laboratory analysis
2D structural representation · PubChem CID 197042 ↗
Chemical Identity
# CAS Registry Number 13103-34-9
Σ IUPAC Name [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] undec-10-enoate
F Molecular Formula C30H44O3
M Molecular Weight 452.67 g/mol
SMILES C=CCCCCCCCCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3CC[C@]12C
InChIKey WSVLPPMCNTCMFS-UHFFFAOYSA-N
Melting Point Oil (liquid at RT) °C
Solubility Insoluble in water; soluble in oils
Biological Half-life 14 days (IM)
PubChem CID 197042 ↗
Pharmacological Profile
Anabolic Rating 100
Androgenic Rating 50
Aromatization Low
Hepatotoxicity None
Detection Time 5 months

Clinical Notes

Dehydrotestosterone — testosterone analogue with an added 1,2-double bond. AR binding is measurable but lower than parent testosterone; the clinically interesting feature is upregulation of erythropoietin production, producing hematocrit drift steeper than any other injectable AAS. Bloodwork pattern: HCT climbs 6–8 percentage points over a 16-week run without compensatory caloric intake changes. Erythrocytosis is the rate-limiting variable, not androgen dose. Aromatisation is low (~half testosterone rate) but estradiol creep occurs on long cycles — AI requirement is patient-specific rather than protocol-wide. Undecylenate ester: 14-day half-life and predictable weekly dosing. Appetite stimulation is direct (hypothalamic NPY pathway) and begins within 2 weeks of protocol initiation.

Known trade names: Equipoise, Boldebal, Boldane

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.